$9.47
5.02% yesterday
NYSE, Nov 15, 10:00 pm CET
ISIN
US05153U1079
Symbol
AURA
Sector
Industry

Aura Biosciences Stock price

$9.47
-0.39 3.96% 1M
+1.97 26.27% 6M
+0.61 6.88% YTD
+1.38 17.06% 1Y
-11.23 54.25% 3Y
-5.33 36.01% 5Y
-5.33 36.01% 10Y
NYSE, Closing price Fri, Nov 15 2024
-0.50 5.02%
ISIN
US05153U1079
Symbol
AURA
Sector
Industry

Key metrics

Market capitalization $469.77m
Enterprise Value $314.47m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.70
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-93.09m
Free Cash Flow (TTM) Free Cash Flow $-74.51m
Cash position $174.38m
EPS (TTM) EPS $-1.73
P/E forward negative
Short interest 3.09%
Show more

Is Aura Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Aura Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Aura Biosciences forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Aura Biosciences forecast:

Buy
100%

Financial data from Aura Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 1.26 1.26
7% 7%
-
-1.26 -1.26
7% 7%
-
- Selling and Administrative Expenses 19 19
14% 14%
-
- Research and Development Expense 71 71
23% 23%
-
-92 -92
20% 20%
-
- Depreciation and Amortization 1.26 1.26
7% 7%
-
EBIT (Operating Income) EBIT -93 -93
20% 20%
-
Net Profit -83 -83
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aura Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aura Biosciences Stock News

Positive
Seeking Alpha
25 days ago
The positive end of phase 2 study data was achieved using bel-sar for the treatment of patients with intermediate lesions and small choroidal melanoma. The global uveal melanoma treatment market is expected to reach $2.4 billion by 2033. Positive data was reported from the phase 1 study, using bel-sar for the treatment of patients with non-muscle invasive bladder cancer.
Neutral
GlobeNewsWire
29 days ago
Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors
Neutral
MarketBeat
about one month ago
Small-cap stocks faced a challenging environment for the last several years as inflation and high interest rates dampened lending opportunities. These companies—which are often in the early stages of development and lack stability—rely heavily on debt to fuel their growth.
More Aura Biosciences News

Company Profile

Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.

Head office United States
CEO Elisabet Pinos
Employees 89
Founded 2007
Website www.aurabiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today